Tvardi Therapeutics Inc (fra:69C) Share Price

Company Profile

Business description
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Contact
3 Sugar Creek Center boulevard
Suite 525
Sugar LandTX77478
USA
T: +1 713 489-8654
https://www.tvarditherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12

Recommended

Stocks that had been posting triple-digit returns are sliding on earnings results.

Karen Gilchrist | 12 August 2026

Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.

Nathan Zaia | 12 August 2026

The “SaaSpocalypse” never arrived. Now, software stocks are positioning for a long-awaited comeback.

Tyger Fitzpatrick | 12 August 2026

Index	Last price	Change	% Change
All Ordinaries	9,381.40	9.10	-0.10%
CAC 40	8,650.56	24.38	-0.28%
DAX 40	26,299.74	31.33	-0.12%
Dow JONES (US)	53,679.46	90.81	-0.17%
FTSE 100	10,772.67	60.48	-0.56%
HKSE	25,396.51	43.66	-0.17%
NASDAQ	26,734.49	146.01	0.55%
Nikkei 225	68,308.59	784.53	1.16%
NZX 50 Index	13,825.30	87.64	0.64%
S&P 500	7,781.29	32.79	0.42%
S&P/ASX 200	9,188.50	4.40	-0.05%
SSE Composite Index	3,926.96	19.71	-0.50%